Namenda

See also: Generic Namenda XR

Namenda is a brand name of memantine, approved by the FDA in the following formulation(s):

NAMENDA (memantine hydrochloride - solution; oral)

• 
  Manufacturer: FOREST LABS
  
  Approval date: April 18, 2005
  
  Strength(s): 2MG/ML ^[RLD]

NAMENDA (memantine hydrochloride - tablet; oral)

• 
  Manufacturer: FOREST LABS
  
  Approval date: October 16, 2003
  
  Strength(s): 10MG ^[RLD], 5MG
  

Has a generic version of Namenda been approved?

No. There is currently no therapeutically equivalent version of Namenda available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Namenda. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Adamantane derivatives in the prevention and treatment of cerebral ischemia
  Patent 5,061,703
  Issued: October 29, 1991
  Inventor(s): Bormann; Joachim & Gold; Markus R. & Schatton; Wolfgang
  Assignee(s): Merz + Co. GmbH & Co.
  A method for the prevention and treatment of cerebral ischemia using an adamantane derivative of the formula ##STR1## wherein R.sub.1 and R.sub.2 are identical or different, representing hydrogen or a straight or branched alkyl group of 1 to 6 C atoms or, in conjunction with N, a heterocyclic group with 5 or 6 ring C atoms; wherein R.sub.3 and R.sub.4 are identical or different, being selected from hydrogen, a straight or branched alkyl group of 1 to 6 C atoms, a cycloalkyl group with 5 or 6 C atoms, and phenyl; wherein R.sub.5 is hydrogen or a straight or branched C.sub.1 -C.sub.6 alkyl group, or a pharmaceutically-acceptable salt thereof, is disclosed.
  
  Patent expiration dates:
  
  
  • April 11, 2015
    
    ✓ 
    Patent use: TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE
  
  

See also...

• Namenda Consumer Information (Drugs.com)
• Namenda Consumer Information (Wolters Kluwer)
• Namenda Solution Consumer Information (Wolters Kluwer)
• Namenda Tablets Consumer Information (Wolters Kluwer)
• Namenda Consumer Information (Cerner Multum)
• Namenda Advanced Consumer Information (Micromedex)
• Namenda AHFS DI Monographs (ASHP)
• Memantine Consumer Information (Wolters Kluwer)
• Memantine Solution Consumer Information (Wolters Kluwer)
• Memantine Tablets Consumer Information (Wolters Kluwer)
• Memantine Consumer Information (Cerner Multum)
• Memantine Advanced Consumer Information (Micromedex)
• Memantine Hydrochloride AHFS DI Monographs (ASHP)